Neohla Bio SComm
Neohla Bio reported total assets of 417,740 € at the end of the 2025 financial year (annual accounts filed with the NBB on 12 May 2026).
The score of Neohla Bio shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Total assets +71 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Neohla Bio's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 12 May 2026
- Year ended 31 Dec 2024filed on 11 Apr 2025
- Year ended 31 Dec 2023filed on 03 Apr 2024
Neohla Bio's financial analysis
- Solvency83.2%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Neohla Bio
Neohla Bio's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0801.148.536
- VAT number
- BE0801148536
- Peppol
- Registered · 0208:0801148536 · as of 10 Nov 2026
- Legal form
- SComm
- Incorporated
- 25 Apr 2023
- Registered office
- 9940 Evergem
- Latest accounts
- 2025 · filed on 12 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Neohla Bio (SComm) has been based in Evergem since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 426,969 € and equity of 347,377 €; its revenue is not published. Its solvency stands at 83.2%, above the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Neohla Bio
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Cabinet Médical Docteur Pierre de Marneffe Research and experimental development on natural sciences and engineering Saint-Georges-sur-Meuse · balance sheet 416,574 €
- Dr. Geert Tits Research and experimental development on natural sciences and engineering Tielt · balance sheet 413,561 €
- Dr. Luc Vanmaele Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 422,775 €
- Managerial Genetics Consulting Research and experimental development on natural sciences and engineering Maaseik · balance sheet 436,140 €
- LB&K Research and experimental development on natural sciences and engineering Sprimont · balance sheet 394,560 €
- IndusFilter Research and experimental development on natural sciences and engineering Ghent · balance sheet 443,685 €
- Dokter Sara Van Soom, huisarts Research and experimental development on natural sciences and engineering Edegem · balance sheet 477,219 €
Frequently asked questions about Neohla Bio
What is the revenue of Neohla Bio?
Neohla Bio files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Neohla Bio?
In Belgium, the VAT number is the company number prefixed with BE: BE0801148536 for Neohla Bio, if the company is VAT-registered. Its company number (CBE) is 0801.148.536.
Where is the registered office of Neohla Bio?
According to the CBE register, the registered office of Neohla Bio is in 9940 Evergem.
What is the equity of Neohla Bio?
At the close of the 2025 financial year, the equity of Neohla Bio amounts to 347,377 €, a solvency of 83.2% of total assets.
Who manages Neohla Bio?
The register lists 2 active mandates at Neohla Bio. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Neohla Bio
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →